Context Molecular biomarkers aim to address the established limitations of clinicopathologic
factors to accurately risk stratify patients with prostate cancer (PCa). Questions remain as to …

Prostate tumours are highly variable in their response to therapies, but clinically available
prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 …

Herein we provide a detailed molecular analysis of the spatial heterogeneity of clinically
localized, multifocal prostate cancer to delineate new oncogenes or tumor suppressors. We …

Despite current risk stratification systems using traditional clinicopathologic factors, many
localized and locally advanced prostate cancers fail radical treatment (ie, radical prostatectomy…

Background Clinical prognostic groupings for localised prostate cancers are imprecise, with
30–50% of patients recurring after image-guided radiotherapy or radical prostatectomy. We …

Purpose: Tumor hypoxia is a negative prognostic factor in multiple cancers, due in part to its
role in causing resistance to radiotherapy. Hypoxia arises in tumor regions distal to blood …

… Berardino de Bari and Alan Dal Pra contributed equally as last author to this article. … ,
Francisco Casquero, Berardino de Bari, Alan Dal Pra, Role of fluorine-18 fluorodeoxyglucose PET/…

Background Intraductal carcinoma (IDC) and cribriform architecture (CA) represent unfavorable
subpathologies in localized prostate cancer. We recently showed that IDC shares a …

Background and purpose Oligometastatic prostate cancer is a new and emerging treatment
field with only few prospective randomized studies published so far. Despite the lack of …

Background Circulating exosomes from prostate cancer (PCa) patients undergoing
radiotherapy are attractive candidate biomarkers for monitoring treatment response. Multiple …